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In relapsed/refractory Hodgkin lymphoma (R/R HL), immunotherapies such as the anti-
programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy
and are playing an increasingly prominent role in treatment. The CD30/CD16A-bispecific
antibody AFM13 is an innate immune cell engager, a first-in-class, tetravalent antibody,
designed to create a bridge between CD30 on HL cells and the CD16A receptor on natural
killer cells and macrophages, to induce tumor cell killing. Early studies of AFM13 have
demonstrated signs of efficacy asmonotherapy for patientswith R/RHLand the combination
of AFM13 with pembrolizumab represents a rational new treatment modality. Here, we
describe a phase 1b, dose-escalation study to assess the safety and preliminary efficacy of
AFM13 in combination with pembrolizumab in patients with R/R HL. The primary objective
was estimating themaximum tolerateddose; the secondaryobjectiveswere to assess safety,
tolerability, antitumor efficacy, pharmacokinetics, and pharmacodynamics. In this heavily
pretreated patient population, treatment with the combination of AFM13 and pem-
brolizumab was generally well tolerated, with similar safety profiles compared to the known
profiles of each agent alone. The combination of AFM13with pembrolizumab demonstrated
an objective response rate of 88% at the highest treatment dose, with an 83% overall response rate for the overall
population. Pharmacokinetic assessment of AFM13 in the combination setting revealed a half-life of up to 20.6 hours. This
proof-of-concept study holds promise as a novel immunotherapy combination worthy of further investigation. This phase
1b study was registered at www.clinicaltrials.gov as NCT02665650. (Blood. 2020;136(21):2401-2409)
Introduction
Patients with Hodgkin lymphoma (HL) have the potential to
be cured or experience long-term remission with risk-adapted
treatment, including chemotherapy and radiotherapy, but 10%
to 30% can develop progressive disease or relapse.1 For patients
with relapsed or refractory HL, 50% or fewer can be cured with
high-dose chemotherapy and autologous stem cell trans-
plantation (ASCT).2,3 Historically, patients with HL who relapse or
progress after ASCT have a poor prognosis with a median overall
survival of ;2 years; however, outcomes have improved sub-
stantially with the development of new drug classes.4,5 A recent
retrospective study reported that, for patients treated with novel
agents (excluding immune checkpoint inhibitors) after post-
ASCT relapse, the median overall survival was 85.6 months.6,7
Brentuximab vedotin (BV) was the first targeted therapy to be
approved (in the United States) for the treatment of HL, indicated
for use in the R/R setting. BV is an antibody drug conjugate
(ADC) that targets CD30 and is conjugated to a cytotoxic agent.
A pivotal phase 2 study reported that BV treatment resulted in an
overall response rate (ORR) of 75% in patients with relapsed/
refractory (R/R) HL and a complete response (CR) rate of 35%.
However, the median progression-free survival after BV treat-
ment is only 5.7 months, and treatment-emergent adverse
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events such as grade 3/4 neutropenia and neuropathy are
common.8
Immunotherapy is a promising new treatment option for HL.
Anti-programmed death-1 (PD-1) antibodies pembrolizumab
and nivolumab have produced striking results in patients with
relapsed or refractory disease as monotherapy with an ORR of
69% for both pembrolizumab and nivolumab.9,10 Both anti-
bodies have been well tolerated with CRs in the range of 22.4%
and 16%, respectively. For HL, therapeutic PD-1 blockade is
largely independent of major histocompatibility complex class I
(MHC-I)-mediated CD81 T-cell responses, whereas MHC II ex-
pression on HL cells was predictive for complete remission,
suggesting CD41 T cells can play a therapeutic role.11 Targeted
ADCs and immunotherapies represent promising approaches
for the treatment of R/R HL. However, additional therapeutic
options and combination therapy are needed with greater and
more durable CR rates with favorable or manageable toxicity
profiles.
AFM13, a first-in-class innate cell engager, is in clinical devel-
opment for treatment of CD301 lymphomas including R/R HL
and peripheral T-cell lymphoma. Developed by the fit-for-
purpose ROCK platform that generates customizable antibodies,
AFM13 is a CD16A/CD30 tetravalent, bispecific antibody stim-
ulating innate immune cells, such as natural killer (NK) cells and
macrophages.12,13 AFM13 binds CD16A on innate cells and binds
CD30 on HL cells, acting as a bridge to recruit and activate innate
immune cells in close proximity to tumor cells.14-16 The activating
receptor CD16A on NK cells facilitates antibody-dependent cell-
mediated cytotoxicity (ADCC) and is the only activating receptor
triggering the cytotoxic activity of naı̈ve human NK cells.15 Re-
search suggests macrophages are also engaged by AFM13,
contributing to the innate immune response.17 AFM13, as the
most clinically advanced innate immune cell engager, was first
studied in HL patients as monotherapy in a dose-escalating phase
1 clinical study for patients with R/R HL.18 AFM13 treatment was
safe, well tolerated, and resulted in objective tumor responses in
multiple patients.18 In this study, AFM13 demonstrated significant
NK cell activation and a decrease of soluble CD30 in peripheral
blood as well as activity in HL patients who received prior BV.18
Phenotypic analysis of lymphoma cells from patients with HL,
refractory to or relapsed after treatment with BV, show that CD30
expression levels are sustained, providing rationale for targeting
CD301 lymphoma with AFM13 in this setting.19 We present the
results of an open-label, multicenter, phase 1b, dose-escalation
study to assess the safety and efficacy of AFM13 in combination
with pembrolizumab in patients with R/R HL.
Patients, materials, and methods
Patients
This study included patients with CD301 classical HL confirmed
by histopathology who were R/R after standard therapy, in-
cluding BV. Where applicable, patients were required to have
completed ASCT$3 months before the first study dose. Further
inclusion criteria were $18 years of age, Eastern Cooperative
Oncology Group performance status ,2, and signed informed
consent. Patients were excluded if they had received prior
therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Patients having certain diseases (other than HL), such as history
of interstitial lung disease, evidence of current central nervous
system involvement, immunodeficiency disorders, or ongoing
systemic corticosteroid treatment, were excluded.
Study design and procedures
This open-label, multicenter, phase 1b, dose-escalation study
with extension cohort was conducted at 14 US sites and 4 sites in
Spain from June 2016 to March 2019. The primary objective of
this study was to estimate the maximum tolerated dose (MTD)/
maximum administered dose (MAD) of the combination of
AFM13 and pembrolizumab. The study consisted of 2 parts; part
1 (primary cohorts) followed a 313 study design in which doses
of AFM13 were escalated in sequential cohorts, whereas the
dose of pembrolizumabwas fixed at 200mg given every 3 weeks
in all patients. If 2 or more dose-limiting toxicity (DLT) events
occurred in an expanded cohort, the next lower dose level was
assigned as the MTD. If the maximum dose of AFM13 (3.0/
7.0 mg/kg) was reached without need to deescalate because of
DLT, it was defined as the MAD. An extension cohort (part 2)
allowed additional evaluation of the MTD or MAD of AFM13
when given in combination with pembrolizumab. Patients were
recruited to the extension cohort with the intention to assess up
to 21 evaluable patients with the selected combination.
Secondary objectives were to assess the safety and tolerability of
increasing doses of AFM13 in combination with pembrolizumab,
to assess antitumor activity of AFM13 in combination with
pembrolizumab, and to evaluate the pharmacokinetic profile of
AFM13 when combined with pembrolizumab. Exploratory anal-
yses included the assessment of relevant biomarkers and to assess
the immunogenicity of AFM13.
The dosing of pembrolizumab was started in week 1 and AFM13
in week 2 (Table 1; supplemental Figure 1). Patients were
assigned to 1 of 3 cohorts (part 1) and received AFM13 IV over 2
or 4 hours (for doses #3 mg/kg and .3 mg/kg, respectively):
cohort 1: 0.1 mg/kg 3 times per week for up to 2 weeks (ie,
week 2 to week 3), 0.5 mg/kg per week for up to 6 weeks
(week 4 to week 9), and 0.5 mg/kg every 3 weeks for up to
Table 1. Dosing schedule for AFM13 and pembrolizumab
as combination therapy















0.1 3 3 0.5 0.5 200
Cohort
2
0.5 3 3 1.5 1.5 200
Cohort
3
3.0 3 3 7.0 7.0 200
Q3W, once every 3 weeks.
*Until disease progression, unacceptable toxicity, cessation of treatment because of
complete response (at investigator’s discretion) or 52 weeks of treatment, whichever
occurred first.
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16 weeks (week 10 to week 25); cohort 2: 0.5 mg/kg 3 times per
week for up to 2 weeks, 1.5 mg/kg/week for up to 6 weeks, and
1.5 mg/kg every 3 weeks for up to 16 weeks; cohort 3: 3.0 mg/kg
3 times per week for up to 2weeks, 7.0mg/kg per week for up to 6
weeks, and 7.0 mg/kg every 3 weeks for up to 16 weeks. The
7.0 mg/kg dose level was used in the clinical development of
AFM13 when given as monotherapy; it was not planned to es-
calate beyond this. All patients received 200 mg of pem-
brolizumab every 3weeks until disease progression, unacceptable
toxicity, cessation of treatment because of CR (at investigator’s
discretion), or 52 weeks of treatment, whichever occurred first.
Study oversight
The protocol was approved by the institutional review board at
each center, and the study was conducted in accordance with
the Declaration of Helsinki and the International Conference on
Harmonization Guidelines for Good Clinical Practice. All the
patients provided written informed consent before study entry.
The principal investigators, in collaboration with the sponsor
(Affimed GmbH), were responsible for the design and oversight
of the study and development of the protocol, available at
ashpublications.org/blood. The sponsor was responsible for the
collection and maintenance of the data. The manuscript was
drafted by a third party (W2O), paid for by the sponsor, and all
authors reviewed and approved the draft manuscript. All the
authors made the decision to submit the manuscript for publi-
cation and attest for the accuracy and completeness of the data
reported and adherence to the protocol.
Study assessments
Safety was assessed by Common Terminology Criteria for Ad-
verse Events, version 4.03, and included clinical examinations,
the assessment of adverse events (AE), DLT, and laboratory
parameters. AE were assessed at each visit, in addition to con-
comitant medications and laboratory screenings. A treatment-
emergent adverse event was defined as an adverse event with an
onset date on or after the first dose of study drugs, and on or
before 30 days after the last dose of study drugs. Patients on the
study were treated with H1/H2 antagonists as a required pre-
medication. After the occurrence of 2 $grade 3 infusion-related
reaction (IRR) events, the protocol was amended to add acet-
aminophen and corticosteroid to the premedication regimen.
AFM13 was only administered from week 2 through week 25,
whereas pembrolizumab continued as a single agent through
week 52 (supplemental Figure 1). In addition, study drug infu-
sions were administered with a safety observation period in
between, and the investigators were allowed to attribute events
to a single drug or the combination therapy. During the safety
assessment and review, each event was accounted for only once
to avoid duplication.
Tumor response was assessed by investigators according to the
revised response criteria for malignant lymphoma (Lugano
classification according to the Cheson criteria, 2014) and by an
independent data monitoring reviewer.20 Tumor imaging (18F
fluorodeoxyglucose positron emission tomography and computed
tomography) was performed on all patients at screening and after
every 12 weeks. Tumor response was determined by the investi-
gator on computed tomography-based radiographic response
and 18F fluorodeoxyglucose positron emission tomography-based
metabolic response separately. Blood samples to measure levels
of soluble CD30 in serum were taken at screening; weeks 7, 13,
and 25; and the final visit. Samples for assessment of anti-drug
antibodies (ADA) against AFM13were taken at screening, week 7,
and at week 25 or the final visit, whichever occurred first. Where
possible, patients were followedupevery 3months from their final
visit to check for disease progression and/or survival status.
All participants in the extension cohort (part 2) participated in an
analysis where their predose AFM13 serum trough levels were
assessed for each AFM13 infusion. Four patients in part 2 had
blood samples taken to assess the pharmacokinetic profile of
AFM13 around their first infusion in week 2 (day 8), after the last
infusion in week 3 (day 19/20), and after the infusion in week 7.
Up to 12 patients enrolled in part 2 who provided additional
informed consent for the translational substudy had 2 biopsies
and additional blood samples taken (group 1 at screening and
before the first pembrolizumab/AFM13 same-day dosing at
week 4, and group 2 at screening and before the second
pembrolizumab dose at week 1).
Pharmacokinetic parameters assessed includedmaximum serum
concentration, area under the curve, volume of distribution, half-
life, and systemic clearance.
Data evaluation
Two populations for analysis were considered. The dose-
determining set consisted of all patients in each cohort who
completed 6 weeks of treatment and patients who discontinued
earlier because of a DLT occurring in this period. This population
was used for the dose escalation in part 1. For all other objectives,
the safety set consisted of all patients that received at least 1 dose
of AMF13 or pembrolizumab. Patients were classified in actual-
treatment-received cohorts. There was no inferential statistical
analysis for primary end points in this study. Results were listed
and summarized using descriptive statistics. For all secondary and




A total of 30 patients were enrolled in this phase 1b, dose-
escalation study (N 5 30). The median age (range) was 34 years
(18-73 years) and the majority (67%) were male. This was a heavily
pretreated patient population (3-7 prior therapies) with 14/30
patients (46.7%) having 3 prior therapies. A total of 12 patients
(40%) had a prior ASCT. All 30 patients had relapsed or re-
fractory disease (43% relapsed, 57% refractory), and 43% of
patients (13/30) had BV as their last prior therapy (Table 2).
Safety
All 30 patients completed the 6-week DLT observation period.
Twelve patients were treated in the dose escalation cohorts
(cohorts 1, 2, and 3) and 18 in the extension cohort (same dose/
schedule as cohort 3). One DLT was observed in a patient in
cohort 3 (missing $25% of AFM13 dose during the DLT period
because of grade 2 IRR), and another DLT was observed in a
patient in the extension cohort (grade 4 IRR). TheMTD of AFM13
was not exceeded in combination with pembrolizumab and the
MAD of AFM13 was determined to be 7 mg/kg. The most
common ($10%) treatment-related AE for AFM13 were IRR
(90%), rash (30%), nausea or pyrexia (23% each), diarrhea (20%),
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fatigue or headache (17% each), and increased aspartate ami-
notransferase (AST) or increased alanine aminotransferase (ALT)
(13% each) (Table 3). The most common treatment-related AE
of grade $3 for AFM13 included IRR (4 patients [13%]), and 1
patient (3%) each with gastritis, hypotension, increased AST,
nausea, neutropenia, or vomiting. Most AE were low grade in
nature andmanageablewith standard-of-care therapies. Themost
common treatment-related AE for AFM13 and pembrolizumab in
combination ($10%) included IRR (8 patients [27%]), rash (6 pa-
tients [20%]), nausea, (7 patients [23%]), fatigue and diarrhea (5
patients [17%] each), and headache and elevated ALT (3 patients
[10%] each). Treatment-related AE of grade $3 for AFM13 and
pembrolizumab in combination included 1 patient (3%) for each of
the following: IRR, nausea, gastritis, and vomiting (Table 3).
No AFM13 dosemodifications were observed in cohorts 1 and 2,
whereas a total of 7 patients required at least 1 AFM13 dose
modification in cohort 3 (4 patients, total n 5 6) and part 2 (3
patients, total n5 18). AFM13 dose interruptions were reported
in 90% of patients from all cohorts (27 patients, N 5 30). A total
of 6 patients experienced AE leading to any study-drug dis-
continuation (5 AFM13 only, 1 AFM13 and pembrolizumab) and
were reported as IRR (n5 5), acute myocardial infarction (n5 1),
myocardial ischemia (n 5 1), gastritis (n 5 1), and hypotension
(n5 1). Both events (acute myocardial infarction and myocardial
ischemia) occurred in the same patient with multiple cardio-
vascular risk factors. All discontinuations were deemed related to
study treatment(s). There was no DLT-related AFM13 discon-
tinuation. A review of the dose exposure does not suggest any
cumulative toxicity in patients as a result of prolonged dosing.
The median dosing durations were 15.7 and 21.3 weeks for
cohort 3 and part 2, respectively, and the median dose in-
tensities were 5.2 and 4.3 mg/kg/week, respectively. These
findings do not correlate with a higher frequency of AEs in cohort
3 compared with part 2 of the study.
There were 4 deaths during the course of the study, 1 case from a
nontreatment-emergent event of vanishing bile duct syndrome
and Steven Johnson syndrome (n5 1); the remaining cases were
due to Aspergillus pneumonia and multiorgan failure (n 5 1),
mycosis fungoides–associated skin infection, septic shock, and
cardiac arrest (n5 1), and respiratory insufficiency and pulmonary
lymphoma (n 5 1); the latter 3 deaths occurred in the context of
progressive disease.
AFM13 trough levels rapidly reached steady state over the first
2 weeks (3 mg/kg 3 times per week); during the subsequent
7 mg/kg weekly dosing period, AFM13 trough concentrations
remained constant, although at a lower level as observed over
the first 2 weeks during the subsequent 7 mg/kg weekly dosing
period. The apparent volume of distribution of up to 3.07 L was
small, indicating that AFM13 is mainly confined to the plasma.
The apparent terminal half-life ranged from 8.7 to 20.6 hours.
Following IV dosing of AFM13 at doses of 3 to 7 mg/kg
coadministered with 200mg pembrolizumab in this combination
trial, the apparent terminal half-life of AFM13 appears similar
in the presence or absence of pembrolizumab.18 After AFM13
treatment initiation, ADA were detected in 17 of 30 patients.
One patient had detectable ADA only at screening. Preliminary
analysis of the data shows that there is no relationship between
the development of ADA and AFM13 pharmacokinetics. Soluble
CD30 levels were significantly reduced in the majority of the
patients across all dose cohorts on week 7 and remained below
baseline level at week 13.
Response to treatment
All 30 patients were evaluable for efficacy. The ORR was 83% (25
patients) by investigator assessment; 37% (11 patients) experi-
enced a complete metabolic response (CMR) and 47% (14 pa-
tients) experienced a partial metabolic response (PMR) (Table 4).
Seven percent (2 patients) showed no metabolic response (NMR),
Table 2. Subject demographics and baseline characteristics
Part 1 Part 2
Cohort 1 (0.1 3
3)/0.5 mg/kg
(n 5 3)
Cohort 2 (0.5 3
3)/1.5 mg/kg
(n 5 3)













29.0 (25, 73) 34.0 (33, 53) 36.0 (26, 49) 27.5 (18, 52) 32.0 (18, 52) 33.5 (18, 73)
Sex
Male 2 (66.7) 2 (66.7) 5 (83.3) 11 (61.1) 16 (66.7) 20 (66.7)
Female 1 (33.3) 1 (33.3) 1 (16.7) 7 (38.9) 8 (33.3) 10 (33.3)
Prior therapies,
no. (%)
3 0 0 0 14 (77.8) 14 (58.3) 14 (46.7)
4 1 (33.3) 1 (33.3) 3 (50.0) 2 (11.1) 5 (20.8) 7 (23.3)
5 0 1 (33.3) 2 (33.3) 0 2 (8.3) 3 (10.0)
6 1 (33.3) 1 (33.3) 1 (16.7) 1 (5.6) 2 (8.3) 4 (13.3)




2 (66.7) 3 (100.0) 4 (66.7) 3 (16.7) 7 (29.2) 12 (40.0)
*MTD was not reached.
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and 10% (3 patients) experienced progressive disease. ORR by
independent assessment demonstrated similar responses as re-
ported in Table 4. At the highest treated dose of 7 mg/kg of
AFM13 in combination with 200 mg pembrolizumab (cohort 3 1
extension, n 5 24), the ORR was 88% (21 patients) for both
assessments; according to the investigator assessment, 42% (10
patients) experienced a CMR and 46% (11 patients) experienced a
PMR. Eight percent (2 patients) had NMR and 4% (1 patient)
experienced progressive disease. According to the indepen-
dent assessment, 46% (11 patients) experienced a CMR,
Table 3. Adverse events related to AFM13 and combination treatment, respectively
AFM13 AFM13 1 pembrolizumab
All grades, ‡10% (n 5 30),
n (%) ‡Grade 3 (n5 30), n (%)
All grades, ‡10%,
n (%)
‡Grade 3 (n 5 30),
n (%)
Any AE 29 (97) 7 (23) 22 (73) 2 (7)
IRR 27 (90) 4 (13) 8 (27) 1 (3)
Rash 9 (30) — 6 (20) —
Nausea 7 (23) 1 (3) 7 (23) 1 (3)
Pyrexia 7 (23) — 4 (13) —
Fatigue 5 (17) — 5 (17) —
Diarrhea 6 (20) — 5 (17) —
Headache 5 (17) — 3 (10) —
Elevated ALT 4 (13) — 3 (10) —
Elevated AST 4 (13) 1 (3) 2 (7) —
Neutropenia 2 (7) 1 (3) 2 (7) —
Gastritis 1 (3) 1 (3) 1 (3) 1 (3)
Vomiting 2 (7) 1 (3) 1 (3) 1 (3)
Hypotension 1 (3) 1 (3) — —
Thrombocytopenia 2 (7) — 2 (7) —
URTI 2 (7) — 2 (7) —
































* * * * *
Cohort 1 (0.1x3)/0.5 mg/kg (n=3)
Cohort 2 (0.5x3)/1.5 mg/kg (n=3)
Cohort 3 and Extension (3.0x3)/7.0 mg/kg (n=24)
Treatment Group
Figure 1. Best response according to tumor volume. The dashed line (230%) represents clinically meaningful responses (30% reduction from baseline). *All assessments are
based on CT scan, CRs are based on PET scans (metabolic assessment) and appear opaque on CT scans. NE, not evaluable; PR, partial response; SD, stable disease.
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42% (10 patients) had a PMR, and 3 (13%) experienced pro-
gressive disease (Table 4). In the subset of patients who were
refractory to BV, 85% (11 patients) achieved an objective response
and 46% (6 patients) achieved a CMR.
Figure 1 shows a waterfall plot with the respective relative
changes in tumor volume during study treatment. The duration
and deepening of response are shown in the swimmer’s plot
(Figure 2). Of the total patients (N 5 30), the vast majority (21
of 25) of the responders (investigator assessment; Table 4)
achieved their best response at their first tumor assessment (ie, at
;13 weeks); 4 patients achieved their best objective response
at the ;26-week assessment or later (Figure 2). A patient’s re-
sponse was considered to be “deepened” when the patients
best overall response improved over time. There was a deep-
ening of response for 1 patient, showing a shift from NMR (no
change in 18F fluorodeoxyglucose uptake from baseline) to a
CMR (at ;13 weeks to ;26 weeks), 2 patients showed a shift
from PMR to CMR (2 patients, at ;13 weeks to ;26 weeks),
whereas 1 patient was not evaluable and shifted to PMR
(;13 weeks to;26 weeks) (Figure 2). Responses did not exactly
occur at 13, 26, and 52 weeks because response evaluations did
not all exactly coincide with the specified time points. The
median duration of any response, CMR, and PMR for all patients
was 9.9 months (95% confidence interval [CI], 8.4-not estimable
[NE]), 10.4 months (95% CI, 2.8-10.4), and 9.0 months (95% CI,
8.4-NE), respectively. The median duration of any response,
CMR, and PMR for patients in the MAD cohort was 9.0 months
(95%CI, 8.4-10.4), 10.4months (95%CI, 2.8-10.4), and 8.7months
(95% CI, 8.4-NE), respectively. Duration of response for individual
patients is shown in supplemental Figure 2 as percent change
from baseline over time. Five patients under study became eli-
gible for stem-cell transplantation. Two additional patients suc-
cessfully transitioned to SCT while off-study (Figure 2).
Discussion
Approximately 10% to 30% of patients with HL relapse after or
are refractory to first-line chemotherapy. The standard of care for
patients with R/R HL is salvage chemotherapy followed by ASCT,
Table 4. Tumor ORR summary
CMR, n (%) PMR, n (%) NMR, n (%) PD, n (%) ORR, n (%)
Investigator assessment
Cohorts 1 and 2 (n 5 6) 1 (17%) 3 (50%) 0 (0%) 2 (33%) 4 (67%)
Cohort 3 and extension (n 5 24) 10 (42%) 11 (46%) 2 (8%) 1 (4%) 21 (88%)
Safety analysis set (n 5 30) 11 (37%) 14 (47%) 2 (7%) 3 (10%) 25 (83%)
Investigator assessment
Cohorts 1 and 2 (n 5 5) 1 (20%) 2 (40%) 2 (40%) 0 (0%) 3 (60%)
Cohort 3 and extension (n 5 24) 11 (46%) 10 (42%) 0 (0%) 3 (13%) 21 (88%)
Safety analysis set (n 5 29) 12 (42%) 12 (42%) 2 (7%) 3 (10%) 24 (83%)
PD, progressive disease.




















Cohort 1 (0.1x3)/0.5 mg/kg (n=3)
Cohort 2 (0.5x3)/1.5 mg/kg (n=3)







Figure 2. Duration and deepening of responses.
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which results in long-term remission for ;50% of patients.2,3 A
milestone was achieved in HL treatment with the development
of BV in post-ASCT consolidation or ASCT failure setting.21 BV as
monotherapy has an ORR of 75% and CR rate of 34%; however,
outside of the consolidation setting, most patients will progress
on BV and require further treatment.8,21
The immune system interacts with developing tumors (ie, cancer
immunoediting) where tumor cells are initially eliminated by the
innate immune system in which the immune system selects
tumor variant generation, followed by immune escape where
these variants expand in an unchecked manner.22,23 HL tumor
cells (Hodgkin and Reed-Sternberg cells) use various mecha-
nisms to immunoevade detection, including downregulation of
surface MHC class I and II expression.21 The PD-1/PD-L1 axis is
one of the major escape mechanisms in HL and provides strong
rationale for immune checkpoint inhibitors as treatment of pa-
tients with HL, revolutionizing therapy protocols over the past
5 years.21,24
Both pembrolizumab and nivolumab have been approved for
the treatment of R/R HL after ASCT and BV failure, whereas
pembrolizumab is also approved for the treatment of transplant-
ineligible patients after BV failure. In a phase 2 study, pem-
brolizumab showed good antitumor activity for patients with R/R
HL (3 cohorts: ASCT followed by BV; ASCT, but without BV after
transplant; salvage chemotherapy and BV), with an ORR of
69.0% and CR rate of 22.4% at 10.1 months.9 With a follow-up of
27.6 months, ORR was 71.9% and CR of 27.6%, with duration of
response at 16.5 months in all patients.25 Pembrolizumab has
antitumor activity with acceptable tolerability in patients with R/R
HL for those treated with BV before or after ASCT and hard-to-
treat chemoresistant patients. However, there remains the un-
met need for improved treatment of patients with R/R HL in
these treatment groups.
NK cells are cytotoxic lymphocytes of innate immunity and are
essential for immunosurveillance of infections and cancer.26 At
high antigen density, NK cells can kill target cells opsonized with
antibodies by ADCC after recognition of the Fc portion of im-
munoglobulin (Ig) with specific Fc receptors. At limiting antigen
density on target cells, an insufficient degree of opsonization of
the target cell by IgG leads to a low level of ADCC and thus
tumor immune escape because of few low-affinity interactions
between the Fc domain and Fc receptors.15 Interestingly, NK
cells are also exhausted by the PD-1/PDL-1 axis in HL and this
is reversible with immune checkpoint inhibitors.21,27 CD16A,
known as FcgRIIIA receptor, is the main receptor facilitating
ADCC via activation of NK cells characterized by release of
cytotoxic granules, death receptor signaling, and release of
pro-inflammatory cytokines. Following activation, NK cells release
preformed granules containing pore-forming perforin and gran-
zymes which trigger apoptosis of target cells.15 In addition to NK
cells, CD16A is expressed on macrophages, monocytes, and g/d
T cells.15
Multiple NK cell-engaging antibodies, as well as bispecific an-
tibodies, targeting immune effector cells and tumor cells, are in
development. AFM13 is a tetravalent bispecific antibody that
targets CD16A/CD30, derived from the ROCK platform.14,18 The
platform is equipped with unique CD16A-specific antibody
variable domains optimized for affinity and avidity to achieve
sustainable activation of NK cells andmacrophages.13 TheCD16A
antibody variable domain of AFM13binds to a specific epitope on
CD16A distinct from the Fc-binding site, resulting in a high
binding affinity that is only slightly inhibited by serum IgGbinding.
ROCK-antibody innate cell engagers are designed to be com-
plementary to other immunotherapeutic approaches, such as
agents that stimulate adaptive immunity and adoptive NK cellular
therapies.13
In the phase I AFM13 monotherapy study in heavily pretreated
HL patients, in 13 patients who received doses of $1.5 mg/kg
AFM13, the ORR was 23% and the disease control rate was 77%.
AFM13 was found to be well-tolerated, safe (MTD was not
reached), and active for heavily pretreated patients with HL,
including BV-refractory patients.18 CD30 expression levels are
sustained on lymphoma cells from patients with HL that are
refractory to, or have relapsed after, treatment with BV, allowing
specific targeting of tumor cells.19
The treatment of AFM13 in combination with pembrolizumab was
well tolerated, with similar safety profiles compared with the known
profiles of each agent alone. IRR and its associated symptoms
continued to be the most common AE related to AFM13 (93%), as
was observed in a phase 1 study of AFM13 asmonotherapy (68%).18
As in the phase 1 study, these events generally resolved with
standard treatment measures. Although this AFM13 and pem-
brolizumab combination trial was a small clinical study, it appears
that the incidence of IRR related to AFM13 is somewhat higher
when administered in combination with pembrolizumab. A larger
randomized study would be required to draw a definitive conclu-
sion on the effect of the combination on the incidence of AFM13-
related IRR. Two patients from part 2 (extension study) of the study
reported adverse events of clinical interest (AST increased). Both
cases corresponded to transient transaminase elevations, with no
relevant clinical signs of inflammation, cholestasis, nor additional
functional liver parameter increase.
All patients in this study had relapsed after or were refractory to
BV treatment. BV targets CD30 but does not diminish or
downregulate CD30 in refractory patients.19 Therefore, prior BV
treatment would not be expected to preclude use of AFM13
after BV treatment of R/R HL disease. Notably, the subset of
patients in this study who were refractory to BV seemed to re-
spond as well to the combination treatment, as did the overall
population with 85% (11 patients) achieving an objective re-
sponse and 46% (6 patients) a CMR.
A limitation of this phase 1b single-arm noncomparative study
design is the inability to assess the individual contribution of
AFM13 vs pembrolizumab to the efficacy observed. None of the
patients had received prior anti-PD1/PD-L1 therapy (ie, they
were all pembrolizumab naı̈ve). At the time this clinical trial
began (June 2016), anti-PD-1 therapy had not yet been ap-
proved for use (US Food and Drug Administration approval for
pembrolizumab in patients with R/R HL was granted in March
2017); hence, it would not have been feasible at that time to
enroll patients that had undergone prior anti-PD-1 therapy.
Nevertheless, the overall response and CMR rates in this study
demonstrate early signs of clinical activity.
This phase 1 study data support further investigation into the
combination of an innate cell engager with a therapy such as an
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immune checkpoint inhibitor that stimulates the adaptive im-
mune system. Ongoing or planned clinical trials for AFM13
include a phase 2 trial to optimize the treatment schedule for
R/R HL (NCT02321592), AFM13 for R/R CD301 cutaneous lym-
phomas (NCT03192202), a combination of cord blood-derived
NK cells, and AFM13 for patients with R/R CD301 lymphoma
(NCT04074746). A registration-directed international phase 2
study is also ongoing to assess AFM13 in patients with R/R CD301
T-cell lymphoma or transformed mycosis fungoides (REDIRECT,
NCT04101331).
In summary, treatment with AFM13 in combination with pem-
brolizumab was well-tolerated with adverse events that were
generallymanageablewith standard treatment and demonstrated
clinical and pharmacodynamic activity.
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